Methods of treating autoimmune disease via CTLA-4IG
AssigneeThe Regents of the University of Michigan
InventorsCraig B. Thompson, Carl H. June
Life of this patent
Estimating the term…
Abstract
The method of immunotherapy of the present invention involves the regulation of the T cell immune response through the activation or suppression/inactivation of the CD28 pathway. Induction of activated T cell lymphokine production occurs upon stimulatory binding of the CD28 surface receptor molecule, even in the presence of conventional immunosuppressants. Inhibition of CD28 receptor binding to an appropriate stimulatory ligand or inactivation of the CD28 signal transduction pathway through other means down-regulates CD28-pathway related T cell lymphokine production and its resulting effects.
Claims24
A method of inhibiting CD28 pathway activation associated with an increase in cellular production of a THCD28 lymphokine in a T cell population, wherein activation occurs by the binding of a stimulatory CD28 ligand to a CD28 receptor stimulatory binding site, the method comprising the steps of:
- a) selecting an inhibitory ligand capable of binding to the stimulatory CD28 ligand;
- b) providing the inhibitory ligand in a biologically compatible form;
- and
- c) administering the inhibitory ligand to the population in an amount sufficient to bind and inhibit the stimulatory ligand from binding the CD28 receptor stimulatory binding site.
A method of suppressing the production of a THCD28 lymphokine by a population of T cells, the method comprising the steps of:
- a) administering an inhibitory ligand which binds a stimulatory ligand for CD28;
- b) providing the ligand in biologically compatible form;
- and
- c) administering the provided ligand in an amount sufficient to suppress production of the lymphokine in the population.
A method of suppressing THCD28 lymphokine production in a patient having a population of T cells, the method comprising the steps of:
- a) providing an inhibitory ligand which binds a natural stimulatory ligand for CD28;
- and
- b) administering the inhibitory ligand in a therapeutically effective amount to the population of T cells.
A method of treating an autoimmune disease in a patient comprising the steps of:
- a) selecting an inhibitory ligand which binds a natural stimulatory ligand to CD28;
- and
- b) administering a therapeutically effective amount of the ligand to the patient.
Dependencies are inferred from the claim text.